ADC Therapeutics SA: ADC Therapeutics Reports Fourth Quarter

ZYNLONTA (loncastuximab tesirine-lpyl) net sales of $19.8 million in Q4 2022, +16.5% year-over-year, and $74.9 million for the full year (FY) 2022 FY 2023 ZYNLONTA net sales expected to grow by

Related Keywords

United States , New Jersey , United Kingdom , Deerfield , Switzerland , Texas , London , City Of , American , Dennis Riedl , Amanda Loshbaugh , Jose Pepe Carmona , Lausanne Biop , Mary Ann Ondish , Mohamed Zaki , Eugenia Litz , Global Head Of Oncology Development At Abbvie , University Of Texas Md Anderson Cancer Center , Company On Twitter , Linkedin , Mitsubishi Tanabe Pharma Corporation , European Commission , Drug Administration , Group Purchasing Organization , Regulatory Agency , American Society Of Hematology , Exchange Commission , Company Annual Report On Form , Development Rd Expenses , Overland Pharmaceuticals , Ameet Mallik , Chief Executive Officer , American Society , Annual Meeting , Chief Medical Officer , Vice President Global Head , Oncology Development , Chief Financial Officer , Infrastructure Investment , Jobs Act , Full Year Financial , Healthcare Royalty Partners , Mitsubishi Tanabe Pharma , Adjusted Net , San Francisco Bay Area , Based Compensation Expense , Facility Agreement , Healthcare Royalty , Private Securities Litigation Reform Act , Swedish Orphan Biovitrum , European Economic Area , Healthcare Royalty Management , Blue Owl , Annual Report , Consolidated Statement , Three Months Ended , Years Ended , Consolidated Balance Sheet , Three Months , Ann Ondish , Therapeutics , Reports , Fourth , Quarter , Bull , Ear , 022 , Financial , Results , Rovides , Business , Updates ,